Loading
Women's Cancer Prevention and Management / Cervical Cancer and HPV Research · Journal article
Revista Fisio&terapia. · September 7, 2026
A consensus or society position rather than new primary data.
This systematic review establishes that persistent infection with high-risk HPV genotypes 16 and 18 is a necessary cofactor for cervical cancer development, influenced by host, behavioural, immunological, and socioeconomic factors. The evidence supports integrated cervical cancer control combining vaccination, screening with molecular HPV DNA testing, diagnosis, and treatment, with emphasis on reducing healthcare access inequalities particularly in low- and middle-income countries.
Systematic review. Studies addressing HPV epidemiology, cervical precursor lesions, cervical cancer, vaccination, and screening strategies; emphasis on evidence from low- and middle-income countries.. Intervention: HPV vaccination and screening for precursor lesions; molecular testing for oncogenic HPV DNA..
HPV is one of the most prevalent sexually transmitted infections worldwide and plays a central role in cervical cancer etiology. Most HPV infections are transient and spontaneously cleared; persistent infection with oncogenic types (particularly 16 and 18) leads to progressive intraepithelial lesions that may evolve to invasive carcinoma without timely intervention. Persistent high-risk HPV infection constitutes a necessary condition for development of most cervical cancers, though carcinogenesis depends also on host-related, behavioural, immunological, and socioeconomic cofactors.
No specific incidence, mortality, or prevalence figures are provided for HPV or cervical cancer.
Clinicians and public health professionals should recognize that cervical cancer control requires a multifaceted approach integrating HPV vaccination, molecular HPV screening, diagnosis, and treatment, with targeted efforts to address healthcare access inequalities that drive persistent high incidence and mortality in under-resourced settings.
A systematic review synthesizing epidemiological evidence and clinical knowledge on HPV and cervical cancer to inform prevention strategy and public health policy, structured by PRISMA guidelines.
As stated by the source record.
Clinicians and public health professionals should recognize that cervical cancer control requires a multifaceted approach integrating HPV vaccination, molecular HPV screening, diagnosis, and treatment, with targeted efforts to address healthcare access inequalities that drive persistent high incidence and mortality in under-resourced settings.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Human papillomavirus (HPV) is one of the most prevalent sexually transmitted infections worldwide and plays a central role in the etiology of cervical cancer. Although most HPV infections are transient and spontaneously cleared by the immune system, persistent infection with oncogenic HPV types, particularly genotypes 16 and 18, may lead to progressive intraepithelial lesions that can evolve into invasive carcinoma in the absence of timely diagnosis and treatment. Cervical cancer remains an important public health problem, particularly in low- and middle-income countries, where inequalities in access to vaccination, screening, and treatment contribute to persistent high incidence and mortality rates. This study aimed to analyze, through a systematic review of the literature, the epidemiology of HPV infection, its relationship with the development of cervical precursor lesions and cancer, and its main clinical and public health impacts. The review was structured according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA 2020) recommendations, including epidemiological studies, systematic reviews, meta-analyses, clinical trials, and technical-scientific documents related to HPV infection, cervical cancer, vaccination, and screening strategies. Epidemiological evidence demonstrates a wide global distribution of HPV infection, with variations according to age, geographic region, and population characteristics. Persistent infection with high-risk HPV constitutes a necessary condition for the development of most cervical cancers, although carcinogenesis also depends on host-related, behavioral, immunological, and socioeconomic cofactors. HPV vaccination and screening for precursor lesions are the main prevention strategies. In Brazil, the progressive implementation of molecular testing for oncogenic HPV DNA represents an important change in the national cervical cancer screening strategy. It is concluded that cervical cancer control requires integration of vaccination, screening, diagnosis, treatment, and follow-up, together with efforts to reduce inequalities in access to healthcare services.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.